Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 ...

Envista Holdings Corporation ("Envista") today announced that the company will participate in a fireside chat at the Evercore HealthCONx Conference on Tuesday, December 3, 2024 from 12:30 ? 1:15 pm ET ...

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

Cardiometabolic disease biotech NeuroBo Pharmaceuticals is shaking up its corporate image with a complete rebrand. | ...

Table 1. Dosage Adjustment, Targeted Dosages, Interactions, and Adverse Effects of Medications Commonly Used to Treat Diabetic Neuropathy a,b,c ...

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

All titles are available on both DVD and Blu-ray unless otherwise noted.

New research describes how sphingolipids can also contribute to arterial plaques and atherosclerosis, revealing a new side to ...

David McCormick, who has been declared the winner of the race by the Associated Press, attended new member orientation just this past week. Congressman Seth Moulton said in a recent interview that he ...

Discover Patanjali’s Madhugrit, an Ayurvedic diabetes solution blending natural herbs with scientific research to manage ...